Tafenoquine Redux: 60 Degrees Pharma’s Malaria Drug Gets Its Turn At US FDA Panel

Extended dosing required for prophylactic indication could raise more advisory committee concerns about safety than the one-time dose of GlaxoSmithKline’s formulation, which was recently approved for prevention of relapse.